<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease (NAFLD) encompasses pure <z:hpo ids='HP_0001397'>steatosis</z:hpo> through <z:e sem="disease" ids="C0400966" disease_type="Disease or Syndrome" abbrv="">nonalcoholic steatohepatitis</z:e> (NASH) and is the most common cause of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> in Western countries </plain></SENT>
<SENT sid="1" pm="."><plain>NASH is a progressive <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> that increases the risk of <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> and <z:e sem="disease" ids="C0745744" disease_type="Disease or Syndrome" abbrv="">end-stage liver disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Interestingly, the global health risk of NAFLD is not confined to the liver </plain></SENT>
<SENT sid="3" pm="."><plain>Compared with those without NAFLD, patients with NAFLD exhibit not only increased liver-related complications and liver-related mortality but also increased risk of developing type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e>, increased risk of post-operative complications after major liver surgery, and increased risk of developing certain <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, including primary <z:hpo ids='HP_0002896'>liver cancer</z:hpo> and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In this review, we discuss the current evidence linking NAFLD with the risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> in the setting of the more complex scenario of other hepatic and extra-hepatic complications that may occur during the natural course of NAFLD </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, we provide a brief description of the putative biological mechanisms underlying such complications, particular emphasis being given to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>We conclude that NAFLD is a complex health problem with implications far beyond the liver </plain></SENT>
<SENT sid="7" pm="."><plain>Hence, it may cause a significant global health burden and the assistance of patients with NAFLD impacts on the work of physicians from many different medical specialties </plain></SENT>
</text></document>